CAMBRIDGE, Mass., June 21, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the appointment of Alexandros Fotopoulos as Senior Vice President, Technical Operations. In this role he will be responsible for the company’s manufacturing and quality efforts from first in human dosing through clinical development and launch. The company also announced the opening of its state-of-the-art laboratory and office space in Woburn, Massachusetts. The 17,000 square foot facility builds upon Dimension’s existing mammalian cell research and process development platform in Cambridge and will enable all GLP material needs required for IND-enabling studies and the production of high-quality AAV vectors across Dimension’s broad product portfolio.
“We are pleased to welcome Alex to the Dimension leadership team. Alex brings substantial expertise in building and leading the development of manufacturing platforms globally to support complex novel biologic therapeutics,” said Dr. Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension. “The major expansion of our research and process development facilities affords us the opportunity to accelerate the advancement of our mammalian platform of AAV vector manufacturing into clinical testing.”
Prior to joining Dimension, Mr. Fotopoulos served for 5 years in leadership roles at Momenta Pharmaceuticals, most recently as Vice President of Technical Operations, responsible for the external development and manufacturing of a portfolio of novel biologics and biosimilars. Previously, he held an 18-year tenure at Biogen, attaining the position of Senior Director of Global Manufacturing Engineering and Facilities. At Biogen, Mr. Fotopoulos managed global clinical and commercial manufacturing facilities, overseeing activities supporting worldwide regulatory filings, launch, and commercialization for products addressing diverse therapeutic areas, including rare diseases and hemophilia. He received his Diploma in chemical engineering at the National Tech University of Athens, his M.S. degree in chemical engineering from Tufts University, and his MBA degree from the F. W. Olin Graduate School of Business at Babson College.
Mr. Fotopoulos stated, “I am excited to join the accomplished team at Dimension, preparing to advance its novel pipeline into the human testing and later stage clinical development. We share the commitment to innovation that will deliver to patients and clinicians the highest quality product in a flexible, scalable cost efficient environment meeting the needs of regulators globally.”
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated advantages of the new facility, increased production and scale capacity, development of manufacturing processes and growth in Dimension’s portfolio, and the progress and acceleration of the company’s R&D programs. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the benefits of the new facility will not be realized; Dimension’s product candidates, including its lead candidate, DTX101, will not successfully be developed or commercialized; and the risks described under the caption “Risk Factors” in Dimension Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Dimension Therapeutics’ additional filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Dimension Therapeutics undertakes no duty to update this information unless required by law.
CONTACT: CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]